Literature DB >> 9255720

A comparison of the standard approach and the NONMEM approach in the estimation of bioavailability in man.

M Combrink1, M L McFadyen, R Miller.   

Abstract

There has recently been concern about confidence intervals calculated using the standard error of parameter estimates from NONMEM, a computer program that uses a non-linear mixed-effects model to calculate relative bioavailability (F), because of possible downward bias of these estimates. In this study an alternate approach, the log-likelihood procedure, was used to calculate the confidence intervals for F from NONMEM. These were then compared with those calculated using the standard error of the parameter estimates, the traditional NONMEM approach, and the standard model-independent method, to determine whether bias exists. By use of data from a single dose, open cross-over study of ibuprofen using 14 healthy male volunteers, NONMEM was shown to give results consistent with those obtained using the standard model-independent method of analysis and could be a useful tool in the determination of F where conditions for using the standard method of analysis are not optimum. The width of the confidence interval for F using the log-likelihood procedure was narrower and non-symmetrical when compared with that obtained using the traditional NONMEM approach. The width of the confidence interval obtained using the traditional NONMEM method was similar to that from the standard approach, however the parameter estimate for F was higher than that obtained from the standard method. This could have been because of an outlier in the data set to which the standard approach is more sensitive. No downward bias was found in the confidence intervals from NONMEM. The bioavailability data set was of relatively low variability and more research with highly variable data is necessary before it can be concluded that the confidence intervals calculated from NONMEM can be used for hypothesis testing.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255720     DOI: 10.1111/j.2042-7158.1997.tb06101.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  5 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

3.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

4.  Comparison of non-compartmental and mixed effect modelling methods for establishing bioequivalence for the case of two compartment kinetics and censored concentrations.

Authors:  Jim H Hughes; Richard N Upton; David J R Foster
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-13       Impact factor: 2.745

5.  Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.

Authors:  J Lötsch; U Muth-Selbach; I Tegeder; K Brune; G Geisslinger
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.